# ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

> **NCT00834080** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Opiate Dependence

## Interventions

- **DRUG:** Medisorb naltrexone 380 mg

## Key facts

- **NCT ID:** NCT00834080
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834080, "ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00834080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*